Skip to main content
Equibles
RGBP logo

RGBP · Regen BioPharma Inc · Documents

Track RGBP — free

Use RGBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.”
View the 10-Q filed Aug 17, 2026
Market Cap
$335,055
Shares
1.68B
Volume · Nov 6 3.62M Avg daily vol (3M) 7.96M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $236.56K unchanged 10-K filed Dec 30, 2025 Quarterly report FY2026 Q3 Revenue $59.07K unchanged 10-Q filed Aug 17, 2026 Latest results Financial results 8-K filed Nov 29, 2024
2026
Nov 2
Current report 8-K Events of Oct 27
Entered into a material agreement

Regen Biopharma entered agreements with Coventry Enterprises: a $125,000 10% unsecured promissory note with $12,500 retained, repayable in 8 equal monthly payments of 17,187.50 Dollars, plus a 36-month equity line up to $10,000,000.

Read from the first part of this long document
Aug 17
Quarterly report 10-Q FY2026 Q3, ended Jun 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $59.07K ▲ unchanged Net loss $637.79K Diluted EPS $0.00
May 14
Quarterly report 10-Q FY2026 Q2, ended Mar 31
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $59.07K ▲ unchanged Net income $991.93K Diluted EPS $0.00
Feb 13
Quarterly report 10-Q FY2026 Q1, ended Dec 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $59.07K ▲ unchanged Net loss $967.85K Diluted EPS -$0.01
Jan 21
Current report 8-K Events of Jan 19
Other events AI summary on its way
2025
Dec 30
Annual report 10-K FY2025, ended Sep 30
Annual report for FY2025
Revenue $236.56K ▲ unchanged Net loss $1.27M Diluted EPS -$0.05
Aug 11
Quarterly report 10-Q FY2025 Q3, ended Jun 30
Quarterly report for FY2025 Q3
Revenue $59.07K ▲ unchanged Net loss $167.29K Diluted EPS -$0.01
May 28
Quarterly report 10-Q FY2025 Q2, ended Mar 31
Quarterly report for FY2025 Q2
Revenue $59.07K ▲ unchanged Net loss $19.35K Diluted EPS $0.00
May 16
Quarterly report 10-Q FY2025 Q1, ended Dec 31
Quarterly report for FY2025 Q1
Revenue $59.07K ▲ unchanged Net loss $515.39K Diluted EPS -$0.13
May 13
Annual report 10-K FY2024, ended Sep 30
Annual report for FY2024
Revenue $236.56K ▲ unchanged Net loss $668.26K Diluted EPS -$0.16
2024
Aug 13
Quarterly report 10-Q FY2024 Q3, ended Jun 30
Quarterly report for FY2024 Q3
Revenue $59.07K ▲ unchanged Net loss $130.12K Diluted EPS -$0.03
Jan 19
Quarterly report 10-Q FY2024 Q1, ended Dec 31
Quarterly report for FY2024 Q1
Revenue $31.64K ▲ unchanged Net loss $349.76K Diluted EPS -$0.10
2023
Nov 20
Annual report 10-K FY2023, ended Sep 30
Annual report for FY2023
Revenue $126.56K ▲ 0.8% Net income $1.16M ▼ 52.7% Diluted EPS $0.29 ▼ 59.2%
2022
Showing 1–50 of 98 documents
Key facts CIK 1589150 CUSIP 75886M300 Visit website Investor relations